Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM‐Line): A two‐center open‐label pilot randomized controlled trial

BACKGROUND: Central venous catheter (CVC) insertion is an important risk factor for venous thromboembolism (VTE) among patients with cancer. Routine use of primary thromboprophylaxis in this patient population is not currently recommended. We sought to assess the feasibility of conducting a randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikesaka, Rick, Siegal, Deborah, Mallick, Ranjeeta, Wang, Tzu‐Fei, Witham, Deborah, Webb, Carolyn, Carrier, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116834/
https://www.ncbi.nlm.nih.gov/pubmed/34027291
http://dx.doi.org/10.1002/rth2.12517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116834/
https://www.ncbi.nlm.nih.gov/pubmed/34027291
http://dx.doi.org/10.1002/rth2.12517

Ejemplares similares